214 related articles for article (PubMed ID: 28161440)
21. Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions.
Seregard S; Oskarsson M; Spângberg B
Exp Eye Res; 1999 Dec; 69(6):671-6. PubMed ID: 10620396
[TBL] [Abstract][Full Text] [Related]
22. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
23. In vivo confocal microscopy of pigmented conjunctival tumors.
Messmer EM; Mackert MJ; Zapp DM; Kampik A
Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1437-45. PubMed ID: 16598465
[TBL] [Abstract][Full Text] [Related]
24. Clinical and immunohistopathological study of conjunctival melanocytic lesions in pediatric and adolescent patients. A case series.
Bogdănici CM; Costea CF; Dumitrescu GF; Sava A; Ciobanu Apostol DG; Scripcariu DV; Nicoară SD; Tănase DM; Andriescu EC; Cărăuleanu A; Danciu M; Sălăvăstru SC; Schmitzer S; Cucu AI; Niagu IA
Rom J Morphol Embryol; 2021; 62(4):907-915. PubMed ID: 35673810
[TBL] [Abstract][Full Text] [Related]
25. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
26. Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with melanoma progression.
Zhang XD; Hersey P
Pathology; 1999 Aug; 31(3):239-46. PubMed ID: 10503270
[TBL] [Abstract][Full Text] [Related]
27. Combined deep penetrating nevi of the conjunctiva are relatively common lesions characterised by BRAFV600E mutation and activation of the beta catenin pathway: a clinicopathological analysis of 34 lesions.
Šekoranja D; Vergot K; Hawlina G; Pižem J
Br J Ophthalmol; 2020 Jul; 104(7):1016-1021. PubMed ID: 31558492
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
29. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
30. HMB-45 antibody reactivity in pigmented lesions of the conjunctiva.
Glasgow BJ; McCall LC; Foos RY
Am J Ophthalmol; 1990 Jun; 109(6):696-700. PubMed ID: 2189315
[TBL] [Abstract][Full Text] [Related]
31. Therapy of melanocytic conjunctival tumors.
Halas JM; Svetlosakova Z; Babal P
Bratisl Lek Listy; 2013; 114(8):446-50. PubMed ID: 23944618
[TBL] [Abstract][Full Text] [Related]
32. Three Types of Nodal Melanocytic Nevi in Sentinel Lymph Nodes of Patients With Melanoma: Pitfalls, Immunohistochemistry, and a Review of the Literature.
Gonzàlez-Farré M; Ronen S; Keiser E; Prieto VG; Aung PP
Am J Dermatopathol; 2020 Oct; 42(10):739-744. PubMed ID: 32271206
[TBL] [Abstract][Full Text] [Related]
33. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
Heegaard S; Jensen OA; Prause JU
Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
[TBL] [Abstract][Full Text] [Related]
35. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
36. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
37. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.
Orosz Z
Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696
[TBL] [Abstract][Full Text] [Related]
38. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
39. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
Garola R; Singh V
Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
[TBL] [Abstract][Full Text] [Related]
40. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]